Showing 6861-6870 of 8838 results for "".
- Biofrontera Inc. Announces FDA Filing of Supplemental New Drug Application for Ameluzhttps://practicaldermatology.com/news/biofrontera-inc-announces-fda-filing-of-supplemental-new-drug-application-for-ameluz/2462237/Biofrontera Inc., a biopharmaceutical company specializing in the commercialization of dermatologic products, today announced that the U.S. Food and Drug Administration (FDA) has issued a "no filing review issues identified" letter regarding the sNDA (supplementary New Drug Application) submitted
- JAK-STAT Inhibitors Not Linked with Significant Increase in Cardiovascular Eventshttps://practicaldermatology.com/news/short-term-cardiovascular-complications-in-dermatology-patients-receiving-jak-stat-inhibitors/2462236/A new systematic review looking at the potential cardiovascular risks associated with Janus kinase–signal transducer and activator of transcription inhibitors (JAK-STATi) showed no safety signals in the short term. The findings bring a nuanced perspective on the safety profile of systemic
- American Academy of Dermatology Issues Updated Guidelines for the Management of Acnehttps://practicaldermatology.com/news/american-academy-of-dermatology-issues-updated-guidelines-for-the-management-of-acne/2462235/Acne is the most common skin condition in the United States, affecting nearly 50 million Americans each year, with symptoms usually beginning in puberty. Acne affects 85% of adolescents and can also often begin or continue in adulthood, especially in women. To help ensure that
- Ceramide and Niacinamide-Containing Moisturizer Safe, Effective with Topical Acne Treatmenthttps://practicaldermatology.com/news/study-reveals-ceramide-and-niacinamide-containing-moisturizer-enhances-topical-acne-treatment/2462234/New research suggests that a moisturizer containing ceramides and niacinamide (CCM) significantly improved lesions from acne vulgaris when combined with anti-acne medication. "Dermatologists often suggests using moisturizers for a wide range of skin problems initiated by acne
- Roflumilast Formulations Show Favorable Tolerability Across Several Trials: Analysishttps://practicaldermatology.com/news/roflumilast-formulations-show-favorable-tolerability-across-several-trials-analysis/2462229/Investigator- and patient-rated assessments indicated that topical roflumilast was tolerable and did not cause discomfort, according to a new analysis of data from several clinical trials.
- Highlights from Maui Derm 2024https://practicaldermatology.com/news/highlights-from-maui-derm-2024/2462227/The Maui Derm 2024 Conference showcased a wide array of advancements in dermatology, from innovative treatments to exciting new therapies, to business opportunities to the latest research. Here, Practical Dermatology recap
- ARCADIA 1 and 2: Nemolizumab Reduces Itch, Sleep Disturbance in Atopic Dermatitishttps://practicaldermatology.com/news/arcadia-nemolizumab-reduces-itch-sleep-disturbance-in-atopic-dermatitis/2462226/Nemolizumab, an interleukin-31 (IL-31) receptor alpha antagonist, demonstrated significant efficacy in adults and adolescents with atopic dermatitis (AD) in a pair of identical trials, according to new study results pre
- For Alopecia Areata, Discontinuation of Baricitinib Linked with Loss of Benefithttps://practicaldermatology.com/news/for-alopecia-areata-discontinuation-of-baricitinib-linked-with-loss-of-benefit/2462225/Results from a randomized substudy of the BRAVE-AA1 study suggested that patients with severe alopecia areata who withdrawal from treatment with baricitinib also lose the treatment benefit.
- Long-Term Analysis Shows Upadacitinib Safe Up to 5 Years for Moderate to Severe ADhttps://practicaldermatology.com/news/long-term-analysis-shows-upadacitinib-safe-up-to-5-years-for-moderate-to-severe-ad/2462222/Upadacitinib for the treatment of moderate-to-severe atopic dermatitis (AD) was shown to have an acceptable safety profile at 5 years, according to a new integrated analysis.
- BE HEARD Analysis: Bimekizumab Maintains Treatment Response at 48 Weeks in HShttps://practicaldermatology.com/news/be-heard-analysis-bimekizumab-maintains-treatment-response-at-48-weeks-in-hs/2462220/A pooled analysis of data from the BE HEARD I and BE HEARD II trials presented at Maui Derm 2024 suggested adults with moderate-to-severe hidradenitis suppurativa (HS) treated with bimekizumab (BKZ) saw a sustained clin